Lindén, Ola, et al. “131 I-Labelled Anti-CD22 MAb (LL2) in Patients With B-Cell Lymphomas Failing Chemotherapy”. Acta Oncologica, vol. 41, no. 3, Jan. 2002, pp. 297-03, doi:10.1080/02841860260088854.